New drug XYA02 takes on tough cancers in first human trial
Disease control
Not yet recruiting
This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…
Phase: PHASE1, PHASE2 • Sponsor: XYone Therapeutics, Inc • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC